Gilead Sciences: Pipeline, Products, Performance, Potential

Table of Contents

Contents

• Latest Results

EXECUTIVE SUMMARY

• Introduction
• Current Financial Position
  • Company Performance
  • Business Segment Performance
  • Geographic Segment Performance
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
    • Discontinued Agreements
  • Employees
• Product Performance Forecasts
• Pipeline Analysis
• Conclusions/Outlook

THERAPEUTIC AREA FOCUS

R&D PIPELINE

ANTIVIRAL

• Marketed Products
  • HIV
    • Atripla
    • Truvada
    • Viread
    • Others
  • Hepatitis
    • Hepsera
• R&D Projects
  • HIV
    • Elvitegravir (GS 9137)
    • GS 9350
  • Hepatitis
    • GS 9190
  • Human papillomavirus
    • GS 9191
    • Discontinued R&D Projects
  • Growth Forecast
    • HIV
    • Hepatitis

OTHERS

• Marketed Products
  • AmBisome
  • Letairis/Volibris
  • Others
• R&D Projects
  • Aztreonam lysine
  • Cicletanine
  • Darusentan
  • GS 9219
  • GS 9310/11
  • GS 9411
  • GS 9450
• Growth Forecast

APPENDIX 1 - FINANCIAL PERFORMANCE

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY Agr eements

• 4AZA Bioscience
• Achillion Pharmaceuticals
• Anadys Pharmaceuticals
• Aspen Pharmacare
• Astellas Pharma
• Bristol-Myers Squibb
• Chimerix
• Dainippon Sumitomo Pharma
• Diatos
• Emory University/Royalty Pharma
• Gladstone Institute of Virology and
• Immunology
• GlaxoSmithKline
• International Partnership for Microbicides/CONRAD
• Japan Tobacco
• LG Life Sciences Ltd
• Merck & Co
• Monogram Biosciences
• Novartis
• Parion Sciences Inc
• Roche

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIA RIE S / JOIN T VEN TURES

• Subsidiaries
• Joint Ventures

APPENDIX 6 - PRODUCT INDEX